Minireview Antibodies as a Probe in Cytochrome P450 Research

Drug Metabolism and Disposition

Volumn 37, Issue 5, 2009, Pages 925-931

  Shou, Magang ^a   Lu, Anthony Y H ^b  

^a AMGEN INC   (United States)

^b RUTGERS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARCINOGEN; CYTOCHROME P450; CYTOCHROME P450 1A1; CYTOCHROME P450 1A2; CYTOCHROME P450 1B1; CYTOCHROME P450 2A6; CYTOCHROME P450 2B6; CYTOCHROME P450 2C19; CYTOCHROME P450 2C8; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 2E1; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; CYTOCHROME P450 4A11; FEXOFENADINE; FLUOXETINE; FLUTICASONE; MIDAZOLAM; MONOCLONAL ANTIBODY; NIFEDIPINE; OMEPRAZOLE; PEPTIDE ANTIBODY; POLYCLONAL ANTIBODY; REPAGLINIDE; TERFENADINE; WARFARIN; XENOBIOTIC AGENT; BLOCKING ANTIBODY; ISOENZYME;

ANTIGEN BINDING; AREA UNDER THE CURVE; CANCER RISK; CANCER SUSCEPTIBILITY; DRUG APPROVAL; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG HALF LIFE; DRUG LABELING; DRUG METABOLISM; DRUG TRANSFORMATION; ENVIRONMENTAL FACTOR; ENZYME SPECIFICITY; ENZYME STRUCTURE; GENE DELETION; GENE DUPLICATION; GENETIC POLYMORPHISM; HEALTH HAZARD; HEREDITY; HUMAN; MEDICAL RESEARCH; MEMBRANE STRUCTURE; MOLECULAR PROBE; NONHUMAN; PHARMACOGENETICS; PHENOTYPE; POLLUTANT; POLYPHARMACY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; SHORT SURVEY; SINGLE NUCLEOTIDE POLYMORPHISM; XENOBIOTIC METABOLISM; ANIMAL; CHEMISTRY; DRUG ANTAGONISM; IMMUNOLOGY; METABOLISM; REVIEW;

ANIMALS; ANTIBODIES, BLOCKING; CYTOCHROME P-450 ENZYME SYSTEM; HUMANS; ISOENZYMES; PHENOTYPE; RISK ASSESSMENT;

EID: 66449097352     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.108.025718     Document Type: Short Survey

References (99)

1. Agundez JA (2004) Cytochrome P450 gene polymorphism and cancer. Curr Drug Metab 5:211-224.
2. Arrington-Sanders R, Hutton N, and Siberry GK (2006) Ritonavir- fluticasone interaction causing Cushing syndrome in HIV-infected children and adolescents. Pediatr Infect Dis J 25:1044-1048.
3. Azie NE, Brater DC, Becker PA, Jones DR, and Hall SD (1998) The interaction of diltiazem with lovastatin and pravastatin. Clin Pharmacol Ther 64:369-377.
4. Backman JT, Karjalainen MJ, Neuvonen M, Laitila J, and Neuvonen PJ (2006) Rofecoxib is a potent inhibitor of cytochrome P450 1A2: studies with tizanidine and caffeine in healthy subjects. Br J Clin Pharmacol 62:345-357.
5. Backman JT, Kyrklund C, Neuvonen M, and Neuvonen PJ (2002) Gemfibrozil greatly increases plasma concentrations of cerivastatin. Clin Pharmacol Ther 72:685-691.
6. Backman JT, Olkkola KT, Aranko K, Himberg JJ, and Neuvonen PJ (1994) Dose of midazolam should be reduced during diltiazem and verapamil treatments. Br J Clin Pharmacol 37:221-225.
7. Bandiera S, Ryan DE, Levin W, and Thomas PE (1985) Evidence for a family of four immunochemically related isozymes of cytochrome P-450 purified from untreated rats. Arch Biochem Biophys 240:478-482.
8. Bartsch H, Nair U, Risch A, Rojas M, Wikman H, and Alexandrov K (2000) Genetic polymorphism of CYP genes, alone or in combination, as a risk modifier of tobacco-related cancers. Cancer Epidemiol Biomarkers Prev 9:3-28.
9. Bernauer U, Heinrich-Hirsch B, Tonnies M, Peter-Matthias W, and Gundert-Remy U (2006) Characterisation of the xenobiotic-metabolizing Cytochrome P450 expression pattern in human lung tissue by immunochemical and activity determination. Toxicol Lett 164:278-288.
10. Bertilsson L (2007) Metabolism of antidepressant and neuroleptic drugs by cytochrome p450s: clinical and interethnic aspects. Clin Pharmacol Ther 82:606-609.
11. Black SD (1992) Membrane topology of the mammalian P450 cytochromes. FASEB J 6:680-685.
12. Black SD and Coon MJ (1982) Structural features of liver microsomal NADPH-cytochrome P-450 reductase. Hydrophobic domain, hydrophilic domain, and connecting region. J Biol Chem 257:5929 -5938.
13. Black SD, Martin ST, and Smith CA (1994) Membrane topology of livermicrosomal cytochrome P450 2B4 determined via monoclonal antibodies directed to the halt-transfer signal. Biochemistry 33:6945-6951.
14. Brands R, Snider MD, Hino Y, Park SS, Gelboin HV, and Rothman JE (1985) Retention of membrane proteins by the endoplasmic reticulum. J Cell Biol 101:1724-1732.
15. Butler MA, Iwasaki M, Guengerich FP, and Kadlubar FF (1989) Human cytochrome P-450PA (P-450IA2), the phenacetin O-deethylase, is primarily responsible for the hepatic 3-demeth- ylation of caffeine and N-oxidation of carcinogenic arylamines. Proc Natl Acad Sci U S A 86:7696 -7700.
16. Cheng KC, Gelboin HV, Song BJ, Park SS, and Friedman FK (1984) Detection and purification of cytochromes P-450 in animal tissues with monoclonal antibodies. JBiol Chem 259:12279-12284.
17. De Lemos-Chiarandini C, Frey AB, Sabatini DD, and Kreibich G (1987) Determination of the membrane topology of the phenobarbital-inducible rat liver cytochrome P-450 isoenzymePB-4 using site-specific antibodies. J Cell Biol 104:209 -219.
18. Edwards RJ (2006) Targeting antipeptide antibodies toward cytochrome P450 enzymes. Methods Mol Biol 320:173-182.
19. Edwards RJ, Adams DA, Watts PS, Davies DS, and Boobis AR (1998) Development of acomprehensive panel of antibodies against the major xenobiotic metabolising forms of cyto- chrome P450 in humans. Biochem Pharmacol 56:377-387.
20. Edwards RJ, Murray BP, Singleton AM, Murray S, Davies DS, and Boobis AR (1993) Identification of the epitope of an anti-peptide antibody which binds to CYP1A2 in many species including man. Biochem Pharmacol 46:213-220.
21. Edwards RJ, Singleton AM, Murray BP, Davies DS, and Boobis AR (1995) Short synthetic peptides exploited for reliable and specific targeting of antibodies to the C-termini of cytochrome P450 enzymes. Biochem Pharmacol 49:39 -47.
22. Edwards RJ, Singleton AM, Murray BP, Murray S, Boobis AR, and Davies DS (1991) Identification of a functionally conserved surface region of rat cytochromes P450IA. Biochem J 278:749 -757.
23. Edwards RJ, Singleton AM, Murray BP, Sesardic D, Rich KJ, Davies DS, and Boobis AR (1990) An anti-peptide antibody targeted to a specific region of rat cytochrome P-450IA2 inhibits enzyme activity. Biochem J 266:497-504.
24. Elshourbagy NA and Guzelian PS (1980) Separation, purification, and characterization of a novel form of hepatic cytochrome P-450 from rats treated with pregnenolone-16 alpha-carbonitrile.J Biol Chem 255:1279 -1285.
25. Emoto C, Murase S, and Iwasaki K (2006) Approach to the prediction of the contribution of major cytochrome P450 enzymes to drug metabolism in the early drug-discovery stage. Xenobiotica 36:671-683.
26. Floren LC, Bekersky I, Benet LZ, Mekki Q, Dressler D, Lee JW, Roberts JP, and Hebert MF (1997) Tacrolimus oral bioavailability doubles with coadministration of ketoconazole. Clin Pharmacol Ther 62:41-49.
27. Foster JR, Elcombe CR, Boobis AR, Davies DS, Sesardic D, McQuade J, Robson RT, Hayward C, and Lock EA (1986) Immunocytochemical localization of cytochrome P-450 in hepatic and extra-hepatic tissues of the rat with a monoclonal antibody against cytochrome P-450 c.Biochem Pharmacol 35:4543-4554.
28. Gelboin HV (1993) Cytochrome P450 and monoclonal antibodies. Pharmacol Rev 45:413-453.
29. Gelboin HV, Goldfarb I, Krausz KW, Grogan J, Korzekwa KR, Gonzalez FJ, and Shou M (1996)Inhibitory and noninhibitory monoclonal antibodies to human cytochrome P450 2E1. Chem Res Toxicol 9:1023-1030.
30. Gelboin HV and Krausz K (2006) Monoclonal antibodies and multifunctional cytochrome P450: drug metabolism as paradigm. J Clin Pharmacol 46:353-372.
31. Gelboin HV, Krausz KW, Goldfarb I, Buters JT, Yang SK, Gonzalez FJ, Korzekwa KR, and Shou M (1995) Inhibitory and non-inhibitory monoclonal antibodies to human cytochrome P450 3A3/4. Biochem Pharmacol 50:1841-1850.
32. Gelboin HV, Krausz KW, Gonzalez FJ, and Yang TJ (1999) Inhibitory monoclonal antibodies to human cytochrome P450 enzymes: a new avenue for drug discovery. Trends Pharmacol Sci 20:432-438.
33. Gelboin HV, Krausz KW, Shou M, Gonzalez FJ, and Yang TJ (1997) A monoclonal antibody inhibitory to human P450 2D6: a paradigm for use in combinatorial determination of individual P450 role in specific drug tissue metabolism.Pharmacogenetics 7:469 -477.
34. Gelboin HV, Shou M, Goldfarb I, Yang TJ, and Krausz K (1998) Monoclonal antibodies to cytochromes P450. Methods Mol Biol 107:227-237.
35. Goldstein JA, Ishizaki T, Chiba K, de Morais SM, Bell D, Krahn PM, and Evans DA (1997) Frequencies of the defective CYP2C19 alleles responsible for the mephenytoin poor metabolizer phenotype in various Oriental, Caucasian, Saudi Arabian and American black populations. Pharmacogenetics 7:59-64.
36. Gomez DY, Wacher VJ, Tomlanovich SJ, Hebert MF, and Benet LZ (1995) The effects of ketoconazole on the intestinal metabolism and bioavailability of cyclosporine. Clin Pharmacol Ther 58:15-19.
37. Gorski JC, Jones DR, Haehner-Daniels BD, Hamman MA, O'Mara EM Jr, and Hall SD (1998) The contribution of intestinal and hepatic CYP3A to the interaction between midazolam and clarithromycin. Clin Pharmacol Ther 64:133-143.
38. Greenblatt DJ, Wright CE, von Moltke LL, Harmatz JS, Ehrenberg BL, Harrel LM, Corbett K, Counihan M, Tobias S, and Shader RI (1998) Ketoconazole inhibition of triazolam and alprazolam clearance: differential kinetic and dynamic consequences. Clin Pharmacol Ther 64:237-247.
39. Guengerich FP (2003) Cytochromes P450, drugs, and diseases. Mol Interv 3:194-204.
40. Guengerich FP, Martin MV, Beaune PH, Kremers P, Wolff T, and Waxman DJ (1986) Characterization of rat and human liver microsomal cytochrome P-450 forms involved in nifedipine oxidation, a prototype for genetic polymorphism in oxidative drug metabolism. J Biol Chem 261:5051-5060.
41. Hong JY and Yang CS (1997) Genetic polymorphism of cytochrome P450 as a biomarker of susceptibility to environmental toxicity. Environ Health Perspect 105 (Suppl 4):759-762.
42. Honig PK, Wortham DC, Zamani K, Conner DP, Mullin JC, and Cantilena LR (1993) Terfe-nadine-ketoconazole interaction. Pharmacokinetic and electrocardiographic consequences.JAMA 269:1513-1518 [Erratum in JAMA 1993 Apr;269:2088].
43. Huang SM, Temple R, Throckmorton DC, and Lesko LJ (2007) Drug interaction studies: study design, data analysis, and implications for dosing and labeling. Clin Pharmacol Ther 81:298 -304.
44. Huang W, Lin YS, McConn DJ, Calamia JC, Totah RA, Isoherranen N, Glodowski M, and Thummel KE (2004) Evidence of significant contribution from CYP3A5 to hepatic drug metabolism. Drug Metab Dispos 32:1434-1445.
45. Ingelman-Sundberg M (2002) Polymorphism of cytochrome P450 and xenobiotic toxicity. Toxicology 181-182:447-452.
46. Johnson EF (2003) The 2002 Bernard B. Brodie Award lecture: deciphering substrate recognition by drug-metabolizing cytochromes P450. Drug Metab Dispos 31:1532-1540.
47. Kassahun K, McIntosh IS, Shou M, Walsh DJ, Rodeheffer C, Slaughter DE, Geer LA, Halpin RA, Agrawal N, and Rodrigues AD (2001) Role of human liver cytochrome P4503A in the metabolism of etoricoxib, a novel cyclooxygenase-2 selective inhibitor. Drug Metab Dispos 29:813-820.
48. Katiyar SK, Matsui MS, and Mukhtar H (2000) Ultraviolet-B exposure of human skin induces cytochromes P450 1A1 and 1B1. J Invest Dermatol 114:328 -333.
49. Kimura M, Ieiri I, Mamiya K, Urae A, and Higuchi S (1998) Genetic polymorphism of cytochrome P450s, CYP2C19, and CYP2C9 in a Japanese population. Ther Drug Monit 20:243-247.
50. Knowles SR, Shapiro LE, and ShearNH (2003) Reactive metabolites and adverse drug reactions: clinical considerations. Clin Rev Allergy Immunol 24:229 -238.
51. Kohler G and Milstein C (1975) Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 256:495-497.
52. Krausz KW, Goldfarb I, Buters JT, Yang TJ, Gonzalez FJ, and Gelboin HV (2001) Monoclonal antibodies specific and inhibitory to human cytochromes P450 2C8, 2C9, and 2C19. Drug Metab Dispos 29:1410-1423.
53. Lechevrel M, Casson AG, Wolf CR, Hardie LJ, Flinterman MB, Montesano R, and Wild CP (1999) Characterization of cytochrome P450 expression in human oesophageal mucosa. Carcinogenesis 20:243-248.
54. Lin JH and Lu AY (1997) Role of pharmacokinetics and metabolism in drug discovery and development. Pharmacol Rev 49:403-449.
55. Lin JH and Lu AY (1998) Inhibition and induction of cytochrome P450 and the clinicalimplications. Clin Pharmacokinet 35:361-390.
56. Lin JH and Lu AY (2001) Interindividual variability in inhibition and induction of cytochrome 450 enzymes. Annu Rev Pharmacol Toxicol 41:535-567.
57. Lu AY, Somogyi A, West S, Kuntzman R, and Conney AH (1972) Pregnenolone-16-carbonitrile:a new type of inducer of drug-metabolizing enzymes. Arch Biochem Biophys 152:457-462.
58. Lu AY, Wang RW, and Lin JH (2003) Cytochrome P450 in vitro reaction phenotyping: a e-evaluation of approaches used for P450 isoform identification. Drug Metab Dispos 31:345-350.
59. McFadyen MC, Breeman S, Payne S, Stirk C, Miller ID, Melvin WT, and Murray GI (1999)Immunohistochemical localization of cytochrome P450 CYP1B1 in breast cancer with monoclonal antibodies specific for CYP1B1. J Histochem Cytochem 47:1457-1464.
60. Mei Q, Tang C, Assang C, Lin Y, Slaughter D, Rodrigues AD, Baillie TA, Rushmore TH, and Shou M (1999) Role of a potent inhibitory monoclonal antibody to cytochrome P-450 3A4 in assessment of human drug metabolism. J Pharmacol Exp Ther 291:749 -759.
61. Mei Q, Tang C, Lin Y, Rushmore TH, and Shou M (2002) Inhibition kinetics of monoclonal antibodies against cytochromes P450. Drug Metab Dispos 30:701-708.
62. Mizutani T (2003) PM frequencies of major CYPs in Asians and Caucasians. Drug Metab Rev35:99 -106.
63. Nagar S and Blanchard RL (2006) Pharmacogenetics of uridine diphosphoglucuronosyltransferase (UGT) 1A family members and its role in patient response to irinotecan. Drug Metab Rev 38:393-409.
64. Nakamura K, Goto F, Ray WA, McAllister CB, Jacqz E, Wilkinson GR, and Branch RA (1985) Interethnic differences in genetic polymorphism of debrisoquin and mephenytoin hydroxyla- tion between Japanese and Caucasian populations. Clin Pharmacol Ther 38:402-408.
65. Ngui JS, Tang W, Stearns RA, Shou M, Miller RR, Zhang Y, Lin JH, and Baillie TA (2000) Cytochrome P450 3A4-mediated interaction of diclofenac and quinidine. Drug Metab Dispos 28:1043-1050.
66. Niemi M, Backman JT, Neuvonen M, and Neuvonen PJ (2003) Effects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics and pharmacodynamics of repaglinide: potentially hazardous interaction between gemfibrozil and repaglinide. Diabetologia 46:347-351.
67. Niu CY, Luo JY, and Hao ZM (2004) Genetic polymorphism analysis of cytochrome P4502C19 in Chinese Uigur and Han populations. Chin J Dig Dis 5:76-80.
68. Obach RS, Walsky RL, Venkatakrishnan K, Gaman EA, Houston JB, and Tremaine LM (2006) The utility of in vitro cytochrome P450 inhibition data in the prediction of drug-druginteractions. J Pharmacol Exp Ther 316:336-348.
69. Omura T and Sato R (1964) The carbon monoxide-binding pigment of liver microsomes. I. Evidence for its hemoprotein nature. J Biol Chem 239:2370-2378.
70. Reik LM, Levin W, Ryan DE, and Thomas PE (1982) Immunochemical relatedness of rat hepatic microsomal cytochromes P-450c and P-450d. J Biol Chem 257:3950-3957.
71. Rendic S and Di Carlo FJ (1997) Human cytochrome P450 enzymes: a status report summarizing their reactions, substrates, inducers, and inhibitors. Drug Metab Rev 29:413-580.
72. Rodrigues AD (1999) Integrated cytochrome P450 reaction phenotyping: attempting to bridgethe gap between cDNA-expressed cytochromes P450 and native human liver microsomes.Biochem Pharmacol 57:465-480.
73. Rodrigues AD and Rushmore TH (2002) Cytochrome P450 pharmacogenetics in drug development: in vitro studies and clinical consequences Curr Drug Metab 3:289-309. [Erratum inCurr Drug Metab 2002 Oct;3:559.].
74. Sai Y, Yang TJ, Krausz KW, Gonzalez FJ, and Gelboin HV (1999) An inhibitory monoclonal antibody to human cytochrome P450 2A6 defines its role in the metabolism of coumarin, 7-ethoxycoumarin and 4-nitroanisole in human liver. Pharmacogenetics 9:229-237.
75. Sanderson S, Emery J, and Higgins J (2005) CYP2C9 gene variants, drug dose, and bleeding risk in warfarin-treated patients: a HuGEnet systematic review and meta-analysis. Genet Med 7:97-104.
76. Shimoda K, Jerling M, Bottiger Y, Yasuda S, Morita S, and Bertilsson L (1999) Pronounced differences in the disposition of clomipramine between Japanese and Swedish patients. J Clin Psychopharmacol 19:393-400.
77. Shou M, Lu T, Krausz KW, SaiY, YangT, Korzekwa KR, Gonzalez FJ, andGelboinHV(2000)Use of inhibitory monoclonal antibodies to assess the contribution of cytochromes P450 tohuman drug metabolism. Eur J Pharmacol 394:199-209.
78. Song BJ, Gelboin HV, Park SS, and Friedman FK (1985) Epitope-relatedness and phenotyping of hepatic cytochromes P-450 with monoclonal antibodies. Biochem J 231:671-676.
79. Song N, Tan W, Xing D, and Lin D (2001) CYP 1A1 polymorphism and risk of lung cancer in relation to tobacco smoking: a case-control study in China. Carcinogenesis 22:11-16.
80. Standop J, Ulrich AB, Schneider MB, Biichler MW, and Pour PM (2002) Differences in the expression of xenobiotic-metabolizing enzymes between islets derived from the ventral and dorsal anlage of the pancreas. Pancreatology 2:510-518.
81. Starkel P, Sempoux C, Van Den Berge V, Stevens M, De Saeger C, Desager JP, and Horsmans Y (1999) CYP 3A proteins are expressed in human neutrophils and lymphocytes but are not induced by rifampicin. Life Sci 64:643-653.
82. Tang C, Shou M, Mei Q, Rushmore TH, and Rodrigues AD (2000) Major role of human liver microsomal cytochrome P450 2C9 (CYP2C9) in the oxidative metabolism of celecoxib, a novel cyclooxygenase-II inhibitor. J Pharmacol Exp Ther 293:453-459.
83. Thomas PE, Lu AY, Ryan D, West SB, Kawalek J, and Levin W (1976a) Immunochemical evidence for six forms of rat liver cytochrome P450 obtained using antibodies against purified rat liver cytochromes P450 and P448. Mol Pharmacol 12:746-758.
84. Thomas PE, Lu AY, Ryan D, West SB, Kawalek J, and Levin W (1976b) Multiple forms of rat liver cytochrome P-450. Immunochemical evidence with antibody against cytochrome P-448. J Biol Chem 251:1385-1391.
85. Thomas PE, Lu AY, West SB, Ryan D, Miwa GT, and Levin W (1977) Accessibility of cytochrome P450 in microsomal membranes: inhibition of metabolism by antibodies to cytochrome P450. Mol Pharmacol 13:819-831.
86. Turner KJ, Macpherson S, Millar MR, McNeilly AS, Williams K, Cranfield M, Groome NP, Sharpe RM, Fraser HM, and Saunders PT (2002) Development and validation of a new monoclonal antibody to mammalian aromatase. J Endocrinol 172:21-30.
87. Van Vleet TR, Klein PJ, and Coulombe RA Jr (2001) Metabolism of aflatoxin B1 by normalhuman bronchial epithelial cells. J Toxicol Environ Health A 63:525-540.
88. Varhe A, Olkkola KT, and Neuvonen PJ (1994) Oral triazolam is potentially hazardous to patients receiving systemic antimycotics ketoconazole or itraconazole. Clin Pharmacol Ther 56 (6 Pt 1):601-607.
89. Wang RW, Newton DJ, Liu NY, Shou M, Rushmore T, and Lu AY (1999) Inhibitory anti- CYP3A4 peptide antibody: mapping of inhibitory epitope and specificity toward other CYP3A isoforms. Drug Metab Dispos 27:167-172.
90. Watkins PB, Wrighton SA, Maurel P, Schuetz EG, Mendez-Picon G, Parker GA, and Guzelian PS (1985) Identification of an inducible form of cytochrome P-450 in human liver. Proc Natl AcadSci USA 82:6310-6314.
91. Williams JA, Hurst SI, Bauman J, Jones BC, Hyland R, Gibbs JP, Obach RS, and Ball SE (2003) Reaction phenotyping in drug discovery: moving forward with confidence? Curr Drug Metab 4:527-534.
92. Williams JA, Hyland R, Jones BC, Smith DA, Hurst S, Goosen TC, Peterkin V, Koup JR, andBall SE (2004) Drug-drug interactions for UDP- glucuronosyltransferase substrates: a phar- macokinetic explanation for typically observed low exposure (AUCi/AUC) ratios. Drug Metab Dispos 32:1201-1208.
93. Wrighton SA, Maurel P, Schuetz EG, Watkins PB, Young B, and Guzelian PS (1985) Identification of the cytochrome P-450 induced by macrolide antibiotics in rat liver as the glucocor- ticoid responsive cytochrome P-450p. Biochemistry 24:2171-2178.
94. Yang TJ, Krausz KW, Sai Y, Gonzalez FJ, and Gelboin HV (1999) Eight inhibitory monoclonal antibodies define the role of individual P-450s in human liver microsomal diazepam, 7-ethoxy- coumarin, and imipramine metabolism. Drug Metab Dispos 27:102-109.
95. Yang TJ, Krausz KW, Shou M, Yang SK, Buters JT, Gonzalez FJ, and Gelboin HV (1998a)Inhibitory monoclonal antibody to human cytochrome P450 2B6. Biochem Pharmacol 55:1633-1640.
96. Yang TJ, Sai Y, Krausz KW, Gonzalez FJ, and Gelboin HV (1998b) Inhibitory monoclonal antibodies to human cytochrome P450 1A2: analysis of phenacetin O-deethylation in human liver. Pharmacogenetics 8:375-382.
97. Yang TJ, Shou M, Korzekwa KR, Gonzalez FJ, Gelboin HV, and Yang SK (1998c) Role o fcDNA-expressed human cytochromes P450 in the metabolism of diazepam. Biochem Pharmacol 55:889-896.
98. Yelton DE and Scharff MD (1981) Monoclonal antibodies: a powerful new tool in biology and medicine. Annu Rev Biochem 50:657-680.
99. Yokono A, Morita S, Someya T, Hirokane G, Okawa M, and Shimoda K (2001) The effect of CYP2C19 and CYP2D6 genotypes on the metabolism of clomipramine in Japanese psychiatric patients. J Clin Psychopharmacol 21:549-555.